Results 171 to 180 of about 12,839 (218)

Distinguishing Features of ILC2s During Type 2 Immune Responses. [PDF]

Eur J Immunol
Jakob MO, Forster PM, Klose CSN.
europepmc   +1 more source

Effects of Tezepelumab in "United Airway Disease" (Asthma and CRSwNP). [PDF]

Case Rep Pulmonol
Lupia C, Piazzetta GL, Pastore D, Lobello N, Preianò M, Chiarella E, Maglio A, Vatrella A, Pelaia G, Pelaia C.   +9 more
europepmc   +1 more source

Immune functions of the esophagus. [PDF]

J Allergy Clin Immunol
Rochman M, Rothenberg ME.
europepmc   +1 more source

Causal effect between systemic inflammatory cytokines and osteoporotic pathological fractures: A bidirectional Mendelian randomization study. [PDF]

Medicine (Baltimore)
Wang H, Wang D.
europepmc   +1 more source

TSLP Production Induced by Poly(I:C) Stimulation Increased in the Presence of Th2 Cytokines in Patients with Severe ECRS. [PDF]

Int Arch Otorhinolaryngol
Inoue A, Tanaka Y, Matsui H, Fukuo A, Kondo M, Wada K.   +5 more
europepmc   +1 more source

A Natural Composite Extract Restores Skin Barrier Function by Modulating Inflammatory, Hydration, and Redox Pathways. [PDF]

J Cosmet Dermatol
Jin C, Cha YJ, Kim HE, Jin Y, Zhang X, Le LTT, Giang NN, Choi K, Lee YH, Kim WH, Choi JH, Chien PN, Yeong HC.   +12 more
europepmc   +1 more source

A skin isolate of <i>Micrococcus luteus</i> negates the <i>Staphylococcus aureus-</i>induced release of type 2 cytokines from keratinocytes. [PDF]

Front Immunol
Elias AE, Pennock JL, McBain AJ, Keevill EJ, O'Neill CA.   +4 more
europepmc   +1 more source

Exacerbation control in chronic obstructive pulmonary disease with tezepelumab: insights from the COURSE trial. [PDF]

J Thorac Dis
Afrose D, Valizadeh M, Sivapalan P.
europepmc   +1 more source

A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases. [PDF]

Cells
Yu M, Chen P, Jin Y, Huang S, Jiang H, Zhou F, Chiu ML, Zhang D.   +7 more
europepmc   +1 more source

Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD. [PDF]

Front Immunol
Song GQ, Chen B, He TL, Hu GQ.
europepmc   +1 more source